IMUC (EOM Pharmaceutical Holdings) Shares Buyback Ratio %: 0.00 (As of Sep. 22, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is EOM Pharmaceutical Holdings Shares Buyback Ratio %?

EOM Pharmaceutical Holdings IMUC Shares Buyback Ratio % is 0.00 as of Sep. 22, 2026.

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

GuruFocus calculates shares buyback ratio using previous shares outstanding minus the current shares outstanding, and then divides by previous shares outstanding. EOM Pharmaceutical Holdings's current shares buyback ratio was 0.00%.

EOM Pharmaceutical Holdings Shares Buyback Ratio % Related Terms

EOM Pharmaceutical Holdings Shares Buyback Ratio % Historical Data

* Premium members only.

The historical data trend for EOM Pharmaceutical Holdings's Shares Buyback Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

EOM Pharmaceutical Holdings Shares Buyback Ratio % Chart

EOM Pharmaceutical Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Shares Buyback Ratio %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -151.29 0.00 0.00 -11.68 0.00

EOM Pharmaceutical Holdings Quarterly Data
Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Mar21 Mar22 Jun22 Sep22 Dec22
Shares Buyback Ratio % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2,602.50 0.00 0.00 0.00 0.00

EOM Pharmaceutical Holdings Shares Buyback Ratio % Calculation

EOM Pharmaceutical Holdings's Shares Buyback Ratio for the fiscal year that ended in Dec. 2025 is calculated as

Shares Buyback Ratio=(Shares Outstanding (EOP) (A: Dec. 2024 ) - Shares Outstanding (EOP) (A: Dec. 2025 )) / Shares Outstanding (EOP) (A: Dec. 2024 )
=(126.50286 - 126.50286) / 126.50286
=0.00%

EOM Pharmaceutical Holdings's Shares Buyback Ratio for the quarter that ended in Dec. 2022 is calculated as

Shares Buyback Ratio=(Shares Outstanding (EOP) (A: Sep. 2022 ) - Shares Outstanding (EOP) (A: Dec. 2022 )) / Shares Outstanding (EOP) (A: Sep. 2022 )
=(113.270751 - 113.270751) / 113.270751
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Shares Buyback Ratio % →
What does a Shares Buyback Ratio % of 0.00 mean?
EOM Pharmaceutical Holdings (IMUC) has a Shares Buyback Ratio % of 0.00 as of Sep. 22, 2026. Share buyback ratio is the percent change of a company's shares outstanding from two periods. View historical data on EOM Pharmaceutical Holdings and its competitors.
Is EOM Pharmaceutical Holdings' Shares Buyback Ratio % too high?
EOM Pharmaceutical Holdings' current Shares Buyback Ratio % is 0.00.
How does EOM Pharmaceutical Holdings' Shares Buyback Ratio % compare to MNTMD and RTTR?
EOM Pharmaceutical Holdings' Shares Buyback Ratio % of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Buyback Ratio % for a Biotechnology company?
A good Shares Buyback Ratio % depends on the Biotechnology industry context. However, Shares Buyback Ratio % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Buyback Ratio % mean?
A high Shares Buyback Ratio % can signal that a stock is expensive relative to its fundamentals. Share buyback ratio is the percent change of a company's shares outstanding from two periods. View historical data on EOM Pharmaceutical Holdings and its competitors. EOM Pharmaceutical Holdings's current Shares Buyback Ratio % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is EOM Pharmaceutical Holdings stock overvalued right now?
EOM Pharmaceutical Holdings (IMUC) has a current Shares Buyback Ratio % of 0.00. The current Shares Buyback Ratio % is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Buyback Ratio % calculated?
Shares Buyback Ratio % is calculated from a company's financial statements. For EOM Pharmaceutical Holdings (IMUC), the current Shares Buyback Ratio % is 0.00 as of Sep. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

EOM Pharmaceutical Holdings Business Description

Address 136 Summit Avenue, Suite 100, Montvale, NJ, USA, 07645
EOM Pharmaceutical Holdings Inc is a clinical-stage biotechnology company that is focused on developing drugs with the potential to transform therapeutic paradigms and improve quality of life in patients suffering from debilitating and sometimes deadly diseases. Its products have been approved in the U.S., rheumatoid arthritis, and inflammatory conditions of the gastrointestinal tract such as Crohn's Disease and Ulcerative Colitis as well as various retina disorders characterized by a breakdown of the blood-retinal barrier such as diabetic retinopathy, Aged related macular degeneration and retinal vein occlusion among others. Its pipeline includes its compound EOM613, an investigational novel dynamically dual-acting immunomodulator.